Litcius/Paper detail

Type I and II interferon signaling in colorectal cancer liver metastasis

Bernadette Mödl, Stefan Moritsch, Daniela Zwolanek, Robert Eferl

2022Cytokine12 citationsDOIOpen Access PDF

Abstract

Metastatic colorectal cancer is one of the leading causes of cancer-related deaths worldwide. Traditional chemotherapy extended the lifespan of cancer patients by only a few months, but targeted therapies and immunotherapy prolonged survival and led to long-term remissions in some cases. Type I and II interferons have direct pro-apoptotic and anti-proliferative effects on cancer cells and stimulate anti-cancer immunity. As a result, interferon production by cells in the tumor microenvironment is in the spotlight of immunotherapies as it affects the responses of anti-cancer immune cells. However, promoting effects of interferons on colorectal cancer metastasis have also been reported. Here we summarize our knowledge about pro- and anti-metastatic effects of type I and II interferons in colorectal cancer liver metastasis and discuss possible therapeutic implications.

Topics & Concepts

Colorectal cancerMetastasisMedicineImmunotherapyCancerInterferonImmune systemCancer researchTumor microenvironmentImmunologyLiver cancerOncologyCancer cellInternal medicineCancer Immunotherapy and Biomarkersinterferon and immune responsesCytokine Signaling Pathways and Interactions